No quarterly revenue total was found in Adaptin Bio, Inc.'s SEC filings.
Adaptin Bio, Inc. (APTN) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).
Revenue
—
Net income
$-1.21M
+20.7% vs year-ago quarter
Operating cash flow
$-450,164
+56.0% vs year-ago quarter
Free cash flow
—
EPS
$-0.14
+22.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
9.23M
+9.2% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- APTN (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Charlotte, NC
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1938571
- Former names
- Unite Acquisition 1 Corp. (until Feb 13, 2025)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$1.2M | -$1.1M | -$1.4M | -$1.7M | -$1.5M |
| Net income | -$1.2M | -$1.1M | -$1.4M | -$1.7M | -$1.5M |
| Diluted EPS | -$0.14 | $0.13 | -$0.16 | -$0.20 | -$0.18 |
| Operating cash flow | -$450,164 | -$596,298 | -$702,876 | -$772,430 | -$1.0M |
| Total assets | $981,452 | $706,117 | $619,159 | $979,474 | $1.7M |
| Total liabilities | $2.6M | $2.5M | $2.1M | $1.9M | $1.2M |
| Stockholders' equity | -$1.7M | -$1.8M | -$1.5M | -$881,078 | $474,409 |
| Cash and investments | $670,488 | $301,309 | $459,174 | $579,089 | $1.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Aug 25, 2026 | Aug 20, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 10-K/A | Amended annual report | Jun 12, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Other events
|
Apr 6, 2026 | Apr 6, 2026 |
| 10-K | Annual report | Apr 1, 2026 | Dec 31, 2025 |
All 75 Adaptin Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.